Preliminary Final Report
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The report indicates a significant decrease in revenue from ordinary activities compared to the previous year, alongside an increase in losses attributable to the owners. Despite these challenges, the company reported an increase in net assets due to a successful capital raise. No dividends were declared during the financial period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Optiscan Imaging Limited on 6ix
Earlier from Optiscan Imaging
- Optiscan Signs New Research Agreement for Breast Study
- Head and Neck Study Progressing Ahead of Schedule
- Optiscan Launches InSpecta Device for Veterinary Medicine
- Halfway Mark Reached in Optiscan Breast Cancer Study
- Second Anniversary of Optiscan and Mayo Clinic Agreement
Later from Optiscan Imaging
- Optiscan Initiates Head and Neck Cancer Study in the US
- Significant Milestone Reached in ACL Digital Pathology Study
- Optiscan Lodges U.S. FDA 510(k) Submission for InForm
- Optiscan Lodges U.S. FDA 510(k) Submission for InVue
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging